Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

May 27, 2024

Study Completion Date

May 27, 2024

Conditions
Rheumatoid Arthritis
Interventions
DRUG

CPL409116

CPL409116 contained in the tablet called PG242 (60 mg)

OTHER

Placebo

Tablets without CPL409116 as an active substance

Trial Locations (10)

10002

"Communal enterprise Hospital No. 1 of the Zhytomyr City Council, consulting and treatment department Research Center", Zhytomyr

85-065

MICS Centrum Medyczne Bydgoszcz, Bydgoszcz

31-011

"Centrum Nowoczesnych Terapii Sp. z o.o. Dobry Lekarz", Krakow

90-644

AMICARE Centrum Medyczne Sp. z o. o., Spółka Komandytowa, Lodz

60-218

Medyczne Centrum Hetmańska, Poznan

22-600

Samodzielny Publiczny Zespół Opieki Zdrowotnej w Tomaszowie Lubelskim, Tomaszów Lubelski

04-141

Wojskowy Instytut Medyczny, Warsaw

05-090

PCS Sp. z o. o., Łady

04050

"Medical center of the limited liability company Medical center Consilium Medical", Kyiv

"Polyclinic of the center of medical services and rehabilitation JSC Company of aviation and rocket technology manufacture", Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Center for Research and Development, Poland

OTHER

lead

Celon Pharma SA

INDUSTRY